Amgen Inc - Net Worth and Insider Trading

Amgen Inc Net Worth

The estimated net worth of Amgen Inc is at least $3.3 Billion dollars as of 2024-07-16. Amgen Inc is the 10% Owner of BeiGene Ltd and owns about 18,943,802 shares of BeiGene Ltd (BGNE) stock worth over $2.8 Billion. Amgen Inc is also the 10% Owner of Neumora Therapeutics Inc and owns about 35,368,653 shares of Neumora Therapeutics Inc (NMRA) stock worth over $418 Million. Details can be seen in Amgen Inc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Amgen Inc has not made any transactions after 2023-09-19 and currently still holds the listed stock(s).

Transaction Summary of Amgen Inc

Amgen Inc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Amgen Inc owns 7 companies in total, including BeiGene Ltd (BGNE) , Kezar Life Sciences Inc (KZR) , and Unilife Corp (UNISQ) among others .

Click here to see the complete history of Amgen Inc’s form 4 insider trades.

Insider Ownership Summary of Amgen Inc

Ticker	Comapny	Transaction Date	Type of Owner
BGNE	BeiGene Ltd	2021-09-10	10 percent owner
KZR	Kezar Life Sciences Inc	2018-06-20	10 percent owner
UNISQ	Unilife Corp	2016-02-22	10 percent owner
		2013-12-17	10 percent owner
		2013-05-30	10 percent owner
		2022-01-06	10 percent owner
		2023-09-19	10 percent owner

Amgen Inc Latest Holdings Summary

Amgen Inc currently owns a total of 2 stocks. Among these stocks, Amgen Inc owns 18,943,802 shares of BeiGene Ltd (BGNE) as of September 10, 2021, with a value of $2.8 Billion and a weighting of 87.14%. Amgen Inc also owns 35,368,653 shares of Neumora Therapeutics Inc (NMRA) as of September 19, 2023, with a value of $418 Million and a weighting of 12.86%.

Latest Holdings of Amgen Inc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
BGNE	BeiGene Ltd	2021-09-10	18,943,802	149.60	2,833,992,779
NMRA	Neumora Therapeutics Inc	2023-09-19	35,368,653	11.83	418,411,165

Holding Weightings of Amgen Inc

Amgen Inc Form 4 Trading Tracker

According to the SEC Form 4 filings, Amgen Inc has made a total of 1 transactions in BeiGene Ltd (BGNE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in BeiGene Ltd is the acquisition of 165,529 shares on September 10, 2021, which cost Amgen Inc around $50 Million.

According to the SEC Form 4 filings, Amgen Inc has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 1,764,705 shares on September 19, 2023, which cost Amgen Inc around $30 Million.

Insider Trading History of Amgen Inc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Amgen Inc Trading Performance

GuruFocus tracks the stock performance after each of Amgen Inc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Amgen Inc is 3.12%. GuruFocus also compares Amgen Inc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Amgen Inc within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Amgen Inc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Amgen Inc

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-7.04
Relative Return to S&P 500(%)	-4.42

Amgen Inc Ownership Network

Ownership Network List of Amgen Inc

No Data

Ownership Network Relation of Amgen Inc

Amgen Inc Owned Company Details

What does BeiGene Ltd do?

Who are the key executives at BeiGene Ltd?

Amgen Inc is the 10 percent owner of BeiGene Ltd. Other key executives at BeiGene Ltd include Chief Financial Officer Julia Aijun Wang , Global Head of R&D Lai Wang , and President and GM China Xiaobin Wu .

BeiGene Ltd (BGNE) Insider Trades Summary

Over the past 18 months, Amgen Inc made no insider transaction in BeiGene Ltd (BGNE). Other recent insider transactions involving BeiGene Ltd (BGNE) include a net sale of 4,186 shares made by Julia Aijun Wang , a net sale of 18,252 shares made by Xiaobin Wu , and a net sale of 6,300 shares made by Lai Wang .

In summary, during the past 3 months, insiders sold 14,914 shares of BeiGene Ltd (BGNE) in total and bought 0 shares, with a net sale of 14,914 shares. During the past 18 months, 5,457,068 shares of BeiGene Ltd (BGNE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,457,068 shares.

BeiGene Ltd (BGNE)'s detailed insider trading history can be found in Insider Trading Tracker table.

BeiGene Ltd Insider Transactions

No Available Data

What does Kezar Life Sciences Inc do?

Who are the key executives at Kezar Life Sciences Inc?

Amgen Inc is the 10 percent owner of Kezar Life Sciences Inc. Other key executives at Kezar Life Sciences Inc include 10 percent owner Morningside Venture Investments Ltd , Chief Business Officer Nicholas Michael Mordwinkin , and 10 percent owner Equal Talent Investments Ltd .

Kezar Life Sciences Inc (KZR) Insider Trades Summary

Over the past 18 months, Amgen Inc made no insider transaction in Kezar Life Sciences Inc (KZR). Other recent insider transactions involving Kezar Life Sciences Inc (KZR) include a net sale of 431,114 shares made by Morningside Venture Investments Ltd ,

In summary, during the past 3 months, insiders sold 0 shares of Kezar Life Sciences Inc (KZR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 431,114 shares of Kezar Life Sciences Inc (KZR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 431,114 shares.

Kezar Life Sciences Inc (KZR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kezar Life Sciences Inc Insider Transactions

No Available Data

What does Unilife Corp do?

Who are the key executives at Unilife Corp?

Amgen Inc is the 10 percent owner of Unilife Corp. Other key executives at Unilife Corp include See Remarks David C Hastings , and See Remarks R Richard Wieland .

Unilife Corp (UNISQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Unilife Corp (UNISQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Unilife Corp (UNISQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Unilife Corp (UNISQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Unilife Corp Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

Amgen Inc is the 10 percent owner of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

Amgen Inc is the 10 percent owner of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epizyme Inc Insider Transactions

No Available Data

What does Vigil Neuroscience Inc do?

Who are the key executives at Vigil Neuroscience Inc?

Amgen Inc is the 10 percent owner of Vigil Neuroscience Inc. Other key executives at Vigil Neuroscience Inc include director & President and CEO Ivana Magovcevic-liebisch , Chief Medical Officer Christopher Silber , and Chief Science Officer Gray David L. F. .

Vigil Neuroscience Inc (VIGL) Insider Trades Summary

Over the past 18 months, Amgen Inc made no insider transaction in Vigil Neuroscience Inc (VIGL). Other recent insider transactions involving Vigil Neuroscience Inc (VIGL) include a net purchase of 4,000 shares made by Ivana Magovcevic-liebisch ,

In summary, during the past 3 months, insiders sold 0 shares of Vigil Neuroscience Inc (VIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vigil Neuroscience Inc (VIGL) were sold and 4,000 shares were bought by its insiders, resulting in a net purchase of 4,000 shares.

Vigil Neuroscience Inc (VIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vigil Neuroscience Inc Insider Transactions

No Available Data

What does Neumora Therapeutics Inc do?

Who are the key executives at Neumora Therapeutics Inc?

Amgen Inc is the 10 percent owner of Neumora Therapeutics Inc. Other key executives at Neumora Therapeutics Inc include 10 percent owner Arch Venture Partners Xii, Llc , director & 10 percent owner Kristina Burow , and director & President & CEO Henry O Gosebruch .

Neumora Therapeutics Inc (NMRA) Insider Trades Summary

Over the past 18 months, Amgen Inc made 1 insider transaction in Neumora Therapeutics Inc (NMRA) with a net purchase of 1,764,705. Other recent insider transactions involving Neumora Therapeutics Inc (NMRA) include a net purchase of 2,007,064 shares made by Kristina Burow , a net purchase of 507,064 shares made by Arch Venture Partners Xii, Llc , and a net purchase of 1,500,000 shares made by Arch Venture Partners X, Llc .

In summary, during the past 3 months, insiders sold 0 shares of Neumora Therapeutics Inc (NMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neumora Therapeutics Inc (NMRA) were sold and 7,293,833 shares were bought by its insiders, resulting in a net purchase of 7,293,833 shares.

Neumora Therapeutics Inc (NMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neumora Therapeutics Inc Insider Transactions

No Available Data

Amgen Inc Mailing Address

Above is the net worth, insider trading, and ownership report for Amgen Inc. You might contact Amgen Inc via mailing address: One Amgen Center Drive, Thousand Oaks Ca 91320.

Discussions on Amgen Inc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.